This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Clark, D.E. Articles by Lannigan, D.A. Search for Related Content PubMed PubMed Citation Articles by Clark, D.E. Articles by Lannigan, D.A.

The Serine/Threonine Protein Kinase, p90 Ribosomal S6 Kinase, Is an Important Regulator of Prostate Cancer Cell Proliferation

Departments of ¹ Microbiology and ² Pathology and ³ Center for Cell Signaling, University of Virginia, Charlottesville, Virginia

Requests for reprints: Deborah Lannigan, Center for Cell Signaling, Hospital West, University of Virginia Health Sciences Center, Box 800577, 7041 Multistory Building, Charlottesville, VA 22908-0577. Phone: 434-924-1144; Fax: 434-924-1236; E-mail: dal5f{at}virginia.edu.

An increase in the activity of mitogen-activated protein kinase (MAPK) has been correlated with the progression of prostate cancer to advanced disease in humans. The serine/threonine protein kinase p90-kDa ribosomal S6 kinase (RSK) is an important downstream effector of MAPK but its role in prostate cancer has not previously been examined. Increasing RSK isoform 2 (RSK2) levels in the human prostate cancer line, LNCaP, enhanced prostate-specific antigen (PSA) expression, an important diagnostic marker for prostate cancer, whereas inhibiting RSK activity using a RSK-specific inhibitor, 3Ac-SL0101, decreased PSA expression. The RSK2 regulation of PSA expression occurred via a mechanism involving both RSK2 kinase activity and its ability to associate with the coactivator, p300. RNA interference of the androgen receptor (AR) showed that the AR was important in the RSK2-mediated increase in PSA expression. RSK levels are higher in 50% of human prostate cancers compared with normal prostate tissue, which suggests that increased RSK levels may participate in the rise in PSA expression that occurs in prostate cancer. Furthermore, 3Ac-SL0101 inhibited proliferation of the LNCaP line and the androgen-independent human prostate cancer line, PC-3. These results suggest that proliferation of some prostate cancer cells is dependent on RSK activity and support the hypothesis that RSK may be an important chemotherapeutic target for prostate cancer.

This article has been cited by other articles:

				A. Thakur, Y. Sun, A. Bollig, J. Wu, H. Biliran, S. Banerjee, F. H. Sarkar, and D. J. Liao Anti-invasive and Antimetastatic Activities of Ribosomal Protein S6 Kinase 4 in Breast Cancer Cells Clin. Cancer Res., July 15, 2008; 14(14): 4427 - 4436. [Abstract] [Full Text] [PDF]

				E. Kuang, Q. Tang, G. G. Maul, and F. Zhu Activation of p90 Ribosomal S6 Kinase by ORF45 of Kaposi's Sarcoma-Associated Herpesvirus and Its Role in Viral Lytic Replication J. Virol., February 15, 2008; 82(4): 1838 - 1850. [Abstract] [Full Text] [PDF]

				H. Vaidyanathan, J. Opoku-Ansah, S. Pastorino, H. Renganathan, M. L. Matter, and J. W. Ramos ERK MAP kinase is targeted to RSK2 by the phosphoprotein PEA-15 PNAS, December 11, 2007; 104(50): 19837 - 19842. [Abstract] [Full Text] [PDF]

				H. V. Heemers and D. J. Tindall Androgen Receptor (AR) Coregulators: A Diversity of Functions Converging on and Regulating the AR Transcriptional Complex Endocr. Rev., December 1, 2007; 28(7): 778 - 808. [Abstract] [Full Text] [PDF]

				M. Ikuta, M. Kornienko, N. Byrne, J. C. Reid, S. Mizuarai, H. Kotani, and S. K. Munshi Crystal structures of the N-terminal kinase domain of human RSK1 bound to three different ligands: Implications for the design of RSK1 specific inhibitors Protein Sci., December 1, 2007; 16(12): 2626 - 2635. [Abstract] [Full Text] [PDF]

				Y.-Y. Cho, K. Yao, H.-G. Kim, B. S. Kang, D. Zheng, A. M. Bode, and Z. Dong Ribosomal S6 Kinase 2 Is a Key Regulator in Tumor Promoter Induced Cell Transformation Cancer Res., September 1, 2007; 67(17): 8104 - 8112. [Abstract] [Full Text] [PDF]

				S. Holder, M. Zemskova, C. Zhang, M. Tabrizizad, R. Bremer, J. W. Neidigh, and M. B. Lilly Characterization of a potent and selective small-molecule inhibitor of the PIM1 kinase Mol. Cancer Ther., January 1, 2007; 6(1): 163 - 172. [Abstract] [Full Text] [PDF]

				M. D. Godeny and P. P. Sayeski ERK1/2 regulates ANG II-dependent cell proliferation via cytoplasmic activation of RSK2 and nuclear activation of elk1 Am J Physiol Cell Physiol, December 1, 2006; 291(6): C1308 - C1317. [Abstract] [Full Text] [PDF]

				V. Giroux, J. Iovanna, and J.-C. Dagorn Probing the human kinome for kinases involved in pancreatic cancer cell survival and gemcitabine resistance FASEB J, October 1, 2006; 20(12): 1982 - 1991. [Abstract] [Full Text] [PDF]

				S. Itoh, B. Ding, T. Shishido, N. Lerner-Marmarosh, N. Wang, N. Maekawa, B. C. Berk, Y. Takeishi, C. Yan, B. C. Blaxall, et al. Role of p90 Ribosomal S6 Kinase-Mediated Prorenin-Converting Enzyme in Ischemic and Diabetic Myocardium Circulation, April 11, 2006; 113(14): 1787 - 1798. [Abstract] [Full Text] [PDF]